Özet:

Objectives: The aim of this study was to present real-world data regarding the efficacy and safety of tenofovir disoproxil fumarate (TDF) in pediatric patients with chronic hepatitis B (CHB). Materials and Methods: In this observational retrospective cohort study, medical records of 10 children with CHB receiving TDF were reviewed. Results: All patients were positive for hepatitis B e antigen (HBeAg) at baseline. HBV-DNA <400 copies/mL was achieved in 70% of the patients, while 20% had undetectable levels of HBV-DNA at last visit. The median HBV-DNA at baseline was approximately 8 log10 copies/mL and decrease in HBV-DNA levels after 3 months, 12 months and at last visit was approximately 3.2 log10 copies/mL, 5.2 log10 copies/mL and 6.1 log10 copies/mL, respectively. All but 1 had (n=9, 90%) elevated transaminases at baseline and serum alanine aminotransferase (ALT) levels were normalized in an average of 10.1 (3.7; 5-16) months in 7 patients. Three nucleos(t)ide-naïve patients (30%) experienced HBeAg loss and seroconversion in 12 to 18 months. There were no observed serious adverse events. Renal function was maintained well through follow-up in all patients. Conclusion: Tenofovir monotherapy is effective in terms of virologic and biochemical responses in pediatric patients with CHB. Tenofovir has a favorable safety profile. Keywords: Antiviral, chronic

Anahtar Kelimeler: